|
|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
$999,501
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
$53,716
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
$260,282
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$182,307
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
|
1R01CA226861-01
|
$382,013
|
$382,013
|
MACIAN, FERNANDO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade
|
1R43CA228319-01
|
$299,794
|
$299,794
|
CHEN, RIDONG
|
APT THERAPEUTICS, INC.
|
|
|
PTEN, Tregs and MDSCs in the tumor microenvironment
|
5R01CA211229-02
|
$347,700
|
$347,700
|
MUNN, DAVID
|
AUGUSTA UNIVERSITY
|
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-03
|
$44,524
|
$44,524
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
REGULATION OF UVEAL MELANOMA CELL FATE BY THE PKC PATHWAY VIA MITF
|
5R01CA193321-04
|
$362,569
|
$362,569
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$2,378
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$5,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$2,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$64,062
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Humanized Anti-Renalase Antibodies for Unresectable Melanoma
|
1R43CA224463-01
|
$299,996
|
$299,996
|
BERKOWITZ, BARRY
|
BESSOR PHARMA, LLC
|
|
|
Passive and active targeting of unnatural chemokine fusions for cancer immunotherapies
|
1F32CA220990-01
|
$61,174
|
$30,587
|
FANG, TAO
|
BOSTON CHILDREN'S HOSPITAL
|
|
|
Cancer Deep Phenotype Extraction from Electronic Medical Records
|
5U24CA184407-06
|
$993,015
|
$327,695
|
SAVOVA, GUERGANA
|
BOSTON CHILDREN'S HOSPITAL
|
|
|
Cancer Biology in the Zebrafish
|
2R01CA103846-16A1
|
$420,375
|
$420,375
|
ZON, LEONARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
|
The MC1R protein palmitoylation in melanoma development
|
1R01CA224432-01A1
|
$386,267
|
$386,267
|
CUI, RUTAO
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Molecular connections among UV exposure, red hair, nevi and melanoma
|
5R01CA193913-03
|
$339,093
|
$339,093
|
CUI, RUTAO
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
PAX3 pathways in melanoma
|
5R01CA184001-05
|
$377,438
|
$377,438
|
LANG, DEBORAH
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Defining Novel Mechanisms of Genome Instability in BRAF-mutant Melanoma
|
1F30CA228388-01
|
$49,524
|
$49,524
|
VITTORIA, MARC
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Elucidating the Regulation and Function of the NF1 tumor suppressor
|
5R01CA111754-13
|
$316,635
|
$158,318
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Role of melanoma-PD-1 in cancer progression: diversity supplement
|
3R01CA190838-02S1
|
$71,600
|
$71,600
|
SCHATTON, TOBIAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Role of melanoma-PD-1 in cancer progression
|
5R01CA190838-02
|
$395,501
|
$395,501
|
SCHATTON, TOBIAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Coordinating tumor differentiation and immune suppression with the metabolic state and treatment outcome
|
5R01CA207982-02
|
$393,195
|
$393,195
|
WIDLUND, HANS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Exploring mechanisms to increase cancer cell antigenicity by modulating lineage-specific transcription in tumors
|
5R03CA212987-02
|
$78,830
|
$78,830
|
WIDLUND, HANS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-03
|
$518,165
|
$259,083
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
|
Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
|
5U01CA217848-02
|
$1,146,076
|
$1,146,076
|
SCHREIBER, STUART
|
BROAD INSTITUTE, INC.
|
|
|
Targeting BPTF in the Therapy of BRAF-mutant Melanoma
|
5R01CA215755-02
|
$617,524
|
$617,524
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
$225,518
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
$9,999
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
$1,920
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-05
|
$1,187,291
|
$29,682
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Development of GIFT4: a B cell focused immunotherapy for cancer
|
5R44CA217365-02
|
$999,997
|
$999,997
|
GUYRE, PAUL
|
CELDARA MEDICAL, LLC
|
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
5K08CA179084-05
|
$112,331
|
$56,166
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
|
Proteomics of Metastatic and Non-Metastatic Uveal Melanoma
|
5R21CA209500-02
|
$172,369
|
$172,369
|
CRABB, JOHN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
|
Role of MIF in myeloma bone homing and drug response
|
5R01CA211073-02
|
$362,569
|
$362,569
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
|
Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation
|
1R41CA224520-01A1
|
$288,105
|
$144,053
|
KRUPNICK, ALEXANDER
|
COURIER THERAPEUTICS, INC.
|
|
|
Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors
|
1R44CA228855-01
|
$264,066
|
$132,033
|
KRONAUGE, JAMES
|
CYTOSITE BIOPHARMA, INC.
|
|
|
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
|
5R50CA211399-03
|
$264,110
|
$66,028
|
BIRD, GREGORY
|
DANA-FARBER CANCER INST
|
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S1
|
$445,796
|
$22,290
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S2
|
$59,495
|
$2,975
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S3
|
$62,500
|
$3,125
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S4
|
$149,528
|
$7,476
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S5
|
$60,691
|
$3,035
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S6
|
$228,108
|
$11,405
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S7
|
$199,806
|
$9,990
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
|
Dana-Farber/Harvard Cancer Center
|
5P30CA006516-53
|
$11,504,298
|
$575,215
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
|
ECOG-ACRIN Network Group Statistics and Data Management Center
|
5U10CA180794-05
|
$7,856,253
|
$785,625
|
GRAY, ROBERT
|
DANA-FARBER CANCER INST
|
|
|
The Cellular Geography of Therapeutic Resistance in Cancer
|
1U2CCA233195-01
|
$2,521,976
|
$832,252
|
HAINING, WILLIAM
|
DANA-FARBER CANCER INST
|
|
Total relevant funding to Melanoma for this search: $158,437,087
|
